Statistics

Total Visits

Views
A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens32

Select a period of time:

Number of views in the range

Views
A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens19

Views

Views
November 20240
December 20240
January 20250
February 20253
March 202513
April 20253
May 20250
Download CSV file
 untranslated
 untranslated

Top country views

Views
Singapore13
United States4
Spain1
United Kingdom1
 

Top cities views

Views
Council Bluffs1